Literature DB >> 12149235

Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation.

Valérie Lapierre1, Anne Aupérin, Hakim Tayebi, Jacqueline Chabod, Philippe Saas, Mauricette Michalet, Sylvie François, Frédéric Garban, Christine Giraud, Dominique Tramalloni, Nadia Oubouzar, Didier Blaise, Matthieu Kuentz, Eric Robinet, Pierre Tiberghien.   

Abstract

We have recently shown that the use of allogeneic granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood hematopoietic stem cell transplantation (PBHSCT), as compared with bone marrow transplantation (BMT), is associated with increased titers of antibodies (Abs) directed against red blood cell ABO antigens. To further evaluate the influence of a G-CSF-mobilized PBHSCT graft on alloimmune Ab responses, we examined the frequency of anti-HLA Abs after transplantation in the setting of the same randomized study, comparing PBHSCT with BMT in adults. Anti-HLA Ab presence was determined by complement-dependent cytotoxicity assay (CDC) and flow cytometry in the recipient before and 30 days after transplantation as well as in the donor before graft donation. The use of PBHSCT was significantly associated with increased detection of anti-HLA immunoglobulin G (IgG) Abs early after transplantation as evidenced by flow cytometry (11 of 24 versus 4 of 27 transplant recipients, P =.03) and, less so, by CDC (5 of 24 versus 1 of 27 transplant recipients, P =.09). The difference between PBHSCT and BMT was further heightened when analysis was restricted to anti-HLA IgG Ab-negative donor/recipient pairs. In such a setting, early anti-HLA Ab was never detected after BMT but was repeatedly detected after PBHSCT (flow cytometry, 6 of 18 versus 0 of 17 transplant recipients, P =.02; CDC, 4 of 23 versus 0 of 26 transplant recipients, P =.04). Importantly, the PBHSCT-associated increase in anti-HLA Ab detection was observed despite a reduction in the median number of platelet-transfusion episodes per patient in PBHSC transplant versus BM transplant recipients (3 platelet-transfusion episodes [range, 1-21] in PBHSCT group vs 6 platelet-transfusion episodes [range, 3-33] in the BMT group; P =.02). In conclusion, this study strongly suggests that G-CSF-mobilized PBHSCT results in an increased incidence of circulating anti-HLA Abs and further confirms that the use of such a graft alters alloimmune Ab responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149235     DOI: 10.1182/blood-2001-11-0039

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation.

Authors:  Ross M Fasano; Ewelina Mamcarz; Sharon Adams; Theresa Donohue Jerussi; Kyoko Sugimoto; Xin Tian; Willy A Flegel; Richard W Childs
Journal:  Br J Haematol       Date:  2014-04-18       Impact factor: 6.998

Review 2.  Immunosuppressive properties of mesenchymal stem cells.

Authors:  Mohamed Abumaree; Mohammed Al Jumah; Rishika A Pace; Bill Kalionis
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

3.  Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation.

Authors:  M S Leffell; K Cao; M Coppage; J A Hansen; J M Hart; N Pereira; S Pereira; N L Reinsmoen; D Senitzer; A Smith; M Torres; R Vega; E Fuchs
Journal:  Tissue Antigens       Date:  2009-10-04

Review 4.  Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sarah Morin-Zorman; Pascale Loiseau; Jean-Luc Taupin; Sophie Caillat-Zucman
Journal:  Front Immunol       Date:  2016-08-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.